128 related articles for article (PubMed ID: 20141435)
1. Relationship of the reduced folate carrier gene polymorphism G80A to methotrexate plasma concentration, toxicity, and disease outcome in childhood acute lymphoblastic leukemia.
Faganel Kotnik B; Dolzan V; Grabnar I; Jazbec J
Leuk Lymphoma; 2010 Apr; 51(4):724-6. PubMed ID: 20141435
[No Abstract] [Full Text] [Related]
2. Association between reduced folate carrier G80A polymorphism and methotrexate toxicity in childhood acute lymphoblastic leukemia: a meta-analysis.
He HR; Liu P; He GH; Dong WH; Wang MY; Dong YL; Lu J
Leuk Lymphoma; 2014 Dec; 55(12):2793-800. PubMed ID: 24597986
[TBL] [Abstract][Full Text] [Related]
3. G80A Single Nucleotide Polymorphism in Reduced Folate Carrier-1 Gene in a Mexican Population and its Impact on Survival in Patients with Acute Lymphoblastic Leukemia.
Candelaria M; Ojeda J; Gutiérrez-Hernández O; Taja-Chayeb L; Vidal-Millán S; Dueñas-González A
Rev Invest Clin; 2016; 68(3):154-62. PubMed ID: 27409003
[TBL] [Abstract][Full Text] [Related]
4. Polymorphism G80A in the reduced folate carrier gene and its relationship to methotrexate plasma levels and outcome of childhood acute lymphoblastic leukemia.
Laverdière C; Chiasson S; Costea I; Moghrabi A; Krajinovic M
Blood; 2002 Nov; 100(10):3832-4. PubMed ID: 12411325
[TBL] [Abstract][Full Text] [Related]
5. The effect of RFC G80A polymorphism in Cretan children with acute lymphoblastic leukemia and its interaction with MTHFR C677T and A1298C polymorphisms.
Karathanasis NV; Stiakaki E; Goulielmos GΝ; Kalmanti M
Int J Lab Hematol; 2014 Aug; 36(4):425-30. PubMed ID: 24237708
[TBL] [Abstract][Full Text] [Related]
6. Polymorphism G80A in the reduced folate carrier gene and its relationship to survival and risk of relapse in acute lymphoblastic leukemia.
Leyva-Vázquez MA; Organista-Nava J; Gómez-Gómez Y; Contreras-Quiroz A; Flores-Alfaro E; Illades-Aguiar B
J Investig Med; 2012 Oct; 60(7):1064-7. PubMed ID: 22914600
[TBL] [Abstract][Full Text] [Related]
7. Reduced folate carrier and methylenetetrahydrofolate reductase gene polymorphisms: associations with clinical outcome in childhood acute lymphoblastic leukemia.
Ashton LJ; Gifford AJ; Kwan E; Lingwood A; Lau DT; Marshall GM; Haber M; Norris MD
Leukemia; 2009 Jul; 23(7):1348-51. PubMed ID: 19340000
[No Abstract] [Full Text] [Related]
8. Association of -24CT, 1249GA, and 3972CT ABCC2 gene polymorphisms with methotrexate serum levels and toxic side effects in children with acute lymphoblastic leukemia.
Sharifi MJ; Bahoush G; Zaker F; Ansari S; Rafsanjani KA; Sharafi H
Pediatr Hematol Oncol; 2014 Mar; 31(2):169-77. PubMed ID: 24552501
[TBL] [Abstract][Full Text] [Related]
9. The association of reduced folate carrier 80G>A polymorphism to outcome in childhood acute lymphoblastic leukemia interacts with chromosome 21 copy number.
Gregers J; Christensen IJ; Dalhoff K; Lausen B; Schroeder H; Rosthoej S; Carlsen N; Schmiegelow K; Peterson C
Blood; 2010 Jun; 115(23):4671-7. PubMed ID: 20335220
[TBL] [Abstract][Full Text] [Related]
10. Effect of polymorphisms in transporter genes on dosing, efficacy and toxicity of maintenance therapy in children with acute lymphoblastic leukemia.
Gervasini G; de Murillo SG; Jiménez M; de la Maya MD; Vagace JM
Gene; 2017 Sep; 628():72-77. PubMed ID: 28710036
[TBL] [Abstract][Full Text] [Related]
11. SLC19A1 hot spot for MTX plasma concentration.
Gutierrez-Camino A; Lopez-Lopez E; Garcia-Orad A
Med Oncol; 2014 Oct; 31(10):204. PubMed ID: 25178938
[No Abstract] [Full Text] [Related]
12. The influence of genetic RFC1, MS and MTHFR polymorphisms on the risk of acute lymphoblastic leukemia relapse in children and the adverse effects of methotrexate.
Niedzielska E; Węcławek-Tompol J; Matkowska-Kocjan A; Chybicka A
Adv Clin Exp Med; 2013; 22(4):579-84. PubMed ID: 23986219
[TBL] [Abstract][Full Text] [Related]
13. Polymorphisms of the SLCO1B1 gene predict methotrexate-related toxicity in childhood acute lymphoblastic leukemia.
Lopez-Lopez E; Martin-Guerrero I; Ballesteros J; Piñan MA; Garcia-Miguel P; Navajas A; Garcia-Orad A
Pediatr Blood Cancer; 2011 Oct; 57(4):612-9. PubMed ID: 21387541
[TBL] [Abstract][Full Text] [Related]
14. Methylenetetrahydrofolate reductase C677T and A1298C gene polymorphisms and therapy-related toxicity in children treated for acute lymphoblastic leukemia and non-Hodgkin lymphoma.
Kantar M; Kosova B; Cetingul N; Gumus S; Toroslu E; Zafer N; Topcuoglu N; Aksoylar S; Cinar M; Tetik A; Eroglu Z
Leuk Lymphoma; 2009 Jun; 50(6):912-7. PubMed ID: 19391036
[TBL] [Abstract][Full Text] [Related]
15. Use of MTHFR C677T polymorphism and plasma pharmacokinetics to predict methotrexate toxicity in patients with acute lymphoblastic leukemia.
Mahmoud LB; Mdhaffar M; Frikha R; Ghozzi H; Hakim A; Sahnoun Z; Elloumi M; Zeghal K
Adv Clin Exp Med; 2018 Aug; 27(8):1061-1068. PubMed ID: 29911750
[TBL] [Abstract][Full Text] [Related]
16. Gene polymorphisms in the folate metabolism and their association with MTX-related adverse events in the treatment of ALL.
Chen Y; Shen Z
Tumour Biol; 2015 Jul; 36(7):4913-21. PubMed ID: 26022160
[TBL] [Abstract][Full Text] [Related]
17. Effects of methylenetetrahydrofolate reductase and reduced folate carrier 1 polymorphisms on high-dose methotrexate-induced toxicities in children with acute lymphoblastic leukemia or lymphoma.
Shimasaki N; Mori T; Samejima H; Sato R; Shimada H; Yahagi N; Torii C; Yoshihara H; Tanigawara Y; Takahashi T; Kosaki K
J Pediatr Hematol Oncol; 2006 Feb; 28(2):64-8. PubMed ID: 16462575
[TBL] [Abstract][Full Text] [Related]
18. Polymorphisms in the methotrexate transport pathway: a new tool for MTX plasma level prediction in pediatric acute lymphoblastic leukemia.
Lopez-Lopez E; Ballesteros J; Piñan MA; Sanchez de Toledo J; Garcia de Andoin N; Garcia-Miguel P; Navajas A; Garcia-Orad A
Pharmacogenet Genomics; 2013 Feb; 23(2):53-61. PubMed ID: 23222202
[TBL] [Abstract][Full Text] [Related]
19. High-dose methotrexate in pediatric acute lymphoblastic leukemia: impact of ABCC2 polymorphisms on plasma concentrations.
Rau T; Erney B; Göres R; Eschenhagen T; Beck J; Langer T
Clin Pharmacol Ther; 2006 Nov; 80(5):468-76. PubMed ID: 17112803
[TBL] [Abstract][Full Text] [Related]
20. Methotrexate pharmacogenetics in Uruguayan adults with hematological malignant diseases.
Giletti A; Vital M; Lorenzo M; Cardozo P; Borelli G; Gabus R; Martínez L; Díaz L; Assar R; Rodriguez MN; Esperón P
Eur J Pharm Sci; 2017 Nov; 109():480-485. PubMed ID: 28887233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
